Form 4: Vivos Therapeutics CEO Ronald Kirk Huntsman Acquires Stock Options and Disposes of Shares

Vivos Therapeutics CEO Ronald Kirk Huntsman acquired 315,421 stock options and disposed of 3,461 common shares, while also holding 69,600 shares indirectly.

Summary

• Ronald Kirk Huntsman, CEO of Vivos Therapeutics, engaged in transactions involving the company's stock.
• He disposed of 3,461 common shares directly.
• He also holds 69,600 common shares indirectly through Coronado V Partners, LLC.
• Huntsman was granted 315,421 stock options with an exercise price of $2.64 on November 26, 2024.
• These options vest in three equal installments annually starting September 7, 2025, and ending September 7, 2027.
• The stock option grant was subject to stockholder approval, which was obtained on November 26, 2024.

Sentiment

Score: 6

Explanation: The document is a routine SEC filing detailing insider transactions. While the stock option grant is positive, the disposal of shares is slightly negative, resulting in a neutral to slightly positive sentiment.

Positives

• The grant of stock options to the CEO aligns his interests with those of the shareholders.
• The vesting schedule of the options encourages long-term performance.

Negatives

• The disposal of 3,461 common shares by the CEO could be interpreted negatively by some investors.

Risks

• The vesting of the stock options is contingent on the CEO's continued service with the company.
• The value of the stock options is dependent on the future performance of the company's stock price.

Future Outlook

The document does not contain any specific forward-looking statements or guidance.

Industry Context

This is a standard SEC Form 4 filing, which is common for publicly traded companies when insiders engage in transactions involving their company's stock. It provides transparency into the ownership changes of company executives.

Comparison to Industry Standards

• Stock option grants are a common form of executive compensation in the biotechnology and medical device industries, similar to companies like Align Technology (ALGN) and InMode (INMD).
• The vesting schedule of the options is typical, with annual vesting over a three-year period, which is consistent with industry practices.
• The exercise price of $2.64 is specific to Vivos Therapeutics and its current stock valuation.

Stakeholder Impact

• The stock option grant could be viewed positively by shareholders as it aligns the CEO's interests with theirs.
• The disposal of shares could be viewed negatively by some shareholders.

Next Steps

• The stock options will vest annually starting September 7, 2025.
• The CEO may exercise the options at any time after they vest.

Key Dates

Keywords

stock options, insider trading, beneficial ownership, Vivos Therapeutics, CEO, Ronald Kirk Huntsman, equity incentive plan, share disposal